摘要
目的观察三氧化二砷(ATO)、全反式维甲酸(ATRA)联合化疗治疗初发急性早幼粒细胞白血病(APL)的疗效和毒副反应。方法 48例初发APL患者随机分为2组,治疗组23例采用ATRA、ATO联合化疗方案治疗,对照组25例采用ATRA治疗。结果治疗组和对照组的完全缓解(CR)率分别为95.7%和92.0%(P>0.05);2组获CR所需时间分别为(25.6±2.2)d、(44.6±2.5)d(P<0.05)。治疗组高白细胞患者的CR率为100.0%(7/7),高于对照组的71.4%(5/7)(P<0.05)。毒副反应治疗组并未较对照组增加(P>0.05)。结论 ATO、ATRA联合化疗可作为初发高白细胞APL患者的首选治疗方案。
Objective To observe the therapeutic efficacy and toxicities of arsenic trioxide （ATO） plus all-trans retinoic acid （ATRA） combined with chemotherapy for newly-diagnosed patients with acute promyelocytic leukemia （APL）. Methods Forty-eight newly-diagnosed patients with APL were divided into two groups,23 patients of the treatment group underwent ATO plus ATRA combined with chemotherapy treatment,25 patients of the control group underwent ATRA treatment alone. Results There was no significantly difference in the complete remission （CR） rate between the two groups （95.7% vs 92.0% ,P 〉0.05）. The period to CR was （25.6±2.2） d in the treatment group, and was （44.6±2.5 ） d in the control group （ P 〈 0.05 ）. The CR rate of the patients with high white blood cell count in the treatment group was 100.0% （7/7） ,and was 71.4% （5/7） in the control group （P 〈0.05）. The toxicities of the treatment group were similar to those of the control group （P 〉 0.05）. Conclusion ATO plus AT-RA combined with chemotherapy regimen is first choice management for the newly-diagnosed APL with high white blood cell count.
出处
《肿瘤基础与临床》
2013年第1期18-21,共4页
journal of basic and clinical oncology
